Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Sanacora, Gerard; R. Johnson, Michael; Khan, Arif; Atkinson, Sarah; Riesenberg, R.; Schronen, Juan; A. Burke, Michael; Zajecka, John; Barra, L; Su, Hong-Lin; A. Posener, Joel; Bui, Khanh; C. Quirk, Michael; M. Piser, Timothy; J. Mathew, Sanjay; Pathak, Sanjeev

doi:10.1038/npp.2016.224

Public

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Published in Neuropsychopharmacology • Sep 29, 2016

Authors:

Gerard Sanacora

Michael R. Johnson

Arif Khan

Abstract

The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...

Subject

Placebo

Major depressive disorder

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!